General Partner
Racquel joined Venrock’s Palo Alto office in 2016 and focuses on pharmaceutical and biotech investments. She currently serves on the boards of MBrace Therapeutics, Topaz Therapeutics and SciThera.
She is also an avid supporter of reproductive access for women and serves on the board of Essential Access Health. Prior to Venrock, Racquel was a founding employee of Clovis Oncology, a biopharmaceutical company focused on acquiring, developing and commercializing targeted small molecule therapies in combination with companion diagnostics. She held a variety of business development and commercial roles, was responsible for the acquisition of four pipeline products and led the commercial launch efforts for the PARP inhibitor program in ovarian cancer. Earlier in her career, Racquel was on the investment team at Domain Associates, where she focused on early-stage healthcare investing. Prior to joining Domain Associates, Racquel was a consultant with Easton Associates (now Navigant Consulting), a management consultancy dedicated to the medical industry.